Contempo 1999
November 10, 1999

High-Dose Chemotherapy for Breast Cancer

Author Affiliations

Author Affiliations: Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY (Drs Antman and Heitjan) and the M. D. Anderson Cancer Center, University of Texas, Austin (Dr Hortobagyi).


Edited by Thomas C. Jefferson, MD, Contributing Editor.

JAMA. 1999;282(18):1701-1703. doi:10.1001/jama.282.18.1701

Breast cancer incidence and mortality have been stable or declining since about 1992, the first decline since statistics were available.1,2

While screening has resulted in a higher percentage of patients with early stage disease and improved survival, mortality at 10 years exceed 60% for those with 10 or more involved lymph nodes or large primary tumors. Virtually all patients who initially present with or later develop metastatic breast cancer ultimately die of their disease.3,4

First Page Preview View Large
First page PDF preview
First page PDF preview